1. Scrip
  2. >>Therapy Areas

Aastrom changes course, stock drops 38%

 
• By Mandy Jackson

Aastrom Biosciences had a strategic review under way before Nick Colangelo joined the company as president and CEO in early March, but it was on his watch that Aastrom announced its decision to end the Phase III REVIVE clinical trial for its cell therapy ixmyelocel-T in critical limb ischemia (CLI) and focus on a smaller, faster Phase IIb ixCELL-DCM trial in dilated cardiomyopathy (DCM).

Aastrom Biosciences had a strategic review under way before Nick Colangelo joined the company as president and CEO in early March, but it was on his watch that Aastrom announced its decision to end the Phase III REVIVE clinical trial for its cell therapy ixmyelocel-T in critical limb ischemia (CLI) and focus on a smaller, faster Phase IIb ixCELL-DCM trial in dilated cardiomyopathy (DCM).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapeutic Category

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

 
• By Kevin Grogan

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.